This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (568) Depression and Mood Disorders; Suicide Prevention (1358)

Published on in Vol 11, No 5 (2022): May

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/34711, first published .
Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study

Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study

Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study

Authors of this article:

Gilmar Gutierrez1 Author Orcid Image ;   Joshua Rosenblat2 Author Orcid Image ;   Emily Hawken3 Author Orcid Image ;   Jennifer Swainson4 Author Orcid Image ;   Gustavo Vazquez3 Author Orcid Image
Article Authors Cited by (1) Tweetations (11) Metrics

Journals

  1. Carolina H, Gilmar G, Casimiro C, Gustavo V. Biweekly vs Triweekly low dose intravenous ketamine acute series for severe major depression: A case report. Journal of Affective Disorders Reports 2023;14:100620 View